Our de novo-designed new class of oral, small molecule drugs with combined targeted and immunotherapeutic modes of action is being developed by our expert clinical team alongside clinicians at The University of Texas MD Anderson Center, the world’s leading cancer research and care center, as part of our strategic collaboration which begun in 2015.

To find out more about our collaboration with The University of Texas MD Anderson Cancer Center, click here

Development Programs

Discovery Research
Lead Optimisation
Candidate Nomination
IND-Enabling Studies
Phase I
Phase II

KA2237 (PI3K-p110β/δ)
Hematological tumors
KA2237 (PI3K-p110β/δ)
Solid tumor immunotherapy
KA2507 (HDAC6)
PD-L1 expressing tumors